Table 3.

Matching-adjusted safety comparisons for epcoritamab vs mosunetuzumab and odronextamab

AEEpcoritamab vs mosunetuzumabEpcoritamab vs odronextamab
CRS (grade ≥3) 0.0% vs 2.2% 0.0% vs 3.9% 
OR for CRS (95% CI) 0.000 (0.000-0.000); P < .001 0.000 (0.000-0.000); P < .001 
ICANS 0.0% vs 4.4% 0.0% vs 0.8% 
OR for ICANS (95% CI) 0.000 (0.000-0.000); P < .001 0.000 (0.000-0.000); P < .001 
AEEpcoritamab vs mosunetuzumabEpcoritamab vs odronextamab
CRS (grade ≥3) 0.0% vs 2.2% 0.0% vs 3.9% 
OR for CRS (95% CI) 0.000 (0.000-0.000); P < .001 0.000 (0.000-0.000); P < .001 
ICANS 0.0% vs 4.4% 0.0% vs 0.8% 
OR for ICANS (95% CI) 0.000 (0.000-0.000); P < .001 0.000 (0.000-0.000); P < .001 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal